NZ747504A - Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies - Google Patents

Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies

Info

Publication number
NZ747504A
NZ747504A NZ747504A NZ74750417A NZ747504A NZ 747504 A NZ747504 A NZ 747504A NZ 747504 A NZ747504 A NZ 747504A NZ 74750417 A NZ74750417 A NZ 74750417A NZ 747504 A NZ747504 A NZ 747504A
Authority
NZ
New Zealand
Prior art keywords
dosage regimens
antibodies
dendritic cell
cell antigen
pharmaceutical compositions
Prior art date
Application number
NZ747504A
Other languages
English (en)
Inventor
Mark Krebs
David Dai
Shantanu Sule
Dania Rabah
David Martin
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Priority to NZ787392A priority Critical patent/NZ787392A/en
Publication of NZ747504A publication Critical patent/NZ747504A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ747504A 2016-04-28 2017-04-27 Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies NZ747504A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ787392A NZ787392A (en) 2016-04-28 2017-04-27 Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662328959P 2016-04-28 2016-04-28
PCT/US2017/029802 WO2017189827A1 (en) 2016-04-28 2017-04-27 Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies

Publications (1)

Publication Number Publication Date
NZ747504A true NZ747504A (en) 2025-08-29

Family

ID=58672794

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ747504A NZ747504A (en) 2016-04-28 2017-04-27 Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies
NZ787392A NZ787392A (en) 2016-04-28 2017-04-27 Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ787392A NZ787392A (en) 2016-04-28 2017-04-27 Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2

Country Status (16)

Country Link
US (2) US20190284281A1 (enExample)
EP (1) EP3448425A1 (enExample)
JP (3) JP7045327B2 (enExample)
KR (5) KR20240033168A (enExample)
CN (2) CN116850282A (enExample)
AU (2) AU2017258191B2 (enExample)
BR (1) BR112018072125A2 (enExample)
CA (1) CA3022116A1 (enExample)
CO (1) CO2018012506A2 (enExample)
EA (1) EA201892443A1 (enExample)
IL (2) IL262514B2 (enExample)
MA (1) MA44763A (enExample)
MX (3) MX2018012945A (enExample)
NZ (2) NZ747504A (enExample)
PH (1) PH12018502278A1 (enExample)
WO (1) WO2017189827A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3672981A4 (en) * 2017-08-22 2021-09-15 Biogen MA Inc. PROCESSES FOR PURIFYING ANTIBODIES PRESENTING REDUCED AGGREGATES WITH HIGH MOLECULAR WEIGHT
WO2020016417A1 (en) 2018-07-19 2020-01-23 Ichnos Sciences S.A. Liquid antibody formulation
KR200494676Y1 (ko) 2020-08-04 2021-12-01 (주) 티나인 버튼식 헤어 염색기
MX2023006474A (es) 2020-12-03 2023-08-16 Biogen Ma Inc Metodos de tratamiento del lupus eritematoso cutaneo y lupus eritematoso sistemico.
WO2023017936A1 (ko) 2021-08-09 2023-02-16 주식회사 인벤테라제약 생체 내 주입 후 대식세포에 의해 탐식 및/또는 대사분해되지 않은 상태로 신장을 통해 소변으로 배출되는 나노 구조물
TW202400652A (zh) * 2022-05-25 2024-01-01 大陸商映恩生物製藥（蘇州）有限公司 抗ｂｄｃａ２抗體及其用途
IL321721A (en) * 2022-12-28 2025-08-01 Duality Biologics Shanghai Co Ltd Antidote conjugation against BDCA2 and its use
WO2025067469A1 (zh) * 2023-09-28 2025-04-03 南京维立志博生物科技股份有限公司 Bdca2单克隆抗体及其和taci组成的融合蛋白及其方法和用途
CN118638234B (zh) * 2024-07-04 2025-10-14 杭州博之锐生物制药有限公司 抗bdca2抗体及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2335725B1 (en) * 2003-04-04 2016-10-12 Genentech, Inc. High concentration antibody and protein formulations
AU2013359419B2 (en) * 2012-12-10 2018-03-15 Biogen Ma Inc. Anti-blood dendritic cell antigen 2 antibodies and uses thereof

Also Published As

Publication number Publication date
KR20240159012A (ko) 2024-11-05
NZ787392A (en) 2025-08-29
AU2017258191A1 (en) 2018-11-15
WO2017189827A1 (en) 2017-11-02
BR112018072125A2 (pt) 2019-03-19
KR20220028150A (ko) 2022-03-08
CN116850282A (zh) 2023-10-10
PH12018502278A1 (en) 2019-09-09
MA44763A (fr) 2019-03-06
EA201892443A1 (ru) 2019-04-30
IL262514B1 (en) 2025-08-01
EP3448425A1 (en) 2019-03-06
IL321561A (en) 2025-08-01
AU2024203240A1 (en) 2024-06-13
JP2024038308A (ja) 2024-03-19
MX2025000037A (es) 2025-02-10
KR102366547B1 (ko) 2022-02-23
US20190284281A1 (en) 2019-09-19
JP7045327B2 (ja) 2022-03-31
US20250289895A1 (en) 2025-09-18
IL262514B2 (en) 2025-12-01
KR20240033168A (ko) 2024-03-12
MX2023008075A (es) 2023-07-18
IL262514A (en) 2018-12-31
CA3022116A1 (en) 2017-11-02
MX2018012945A (es) 2019-03-06
AU2017258191B2 (en) 2024-06-13
JP2022084782A (ja) 2022-06-07
CN109475623A (zh) 2019-03-15
KR20250088784A (ko) 2025-06-17
KR20190002563A (ko) 2019-01-08
CN109475623B (zh) 2023-05-26
JP2019520316A (ja) 2019-07-18
CO2018012506A2 (es) 2018-12-14

Similar Documents

Publication Publication Date Title
PH12018502278A1 (en) Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies
MX2024007633A (es) Conjugados de citoquina para el tratamiento de enfermedades proliferativas e infecciosas.
EP4344706A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
PH12017500803A1 (en) Anti-pd-1 antibodies
WO2016081518A3 (en) Engineered gamma delta t-cells
GEP20247693B (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
EP4382164A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
TN2016000094A1 (en) Inhibitors of bruton's tyrosine kinase.
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MX2018010032A (es) Formulaciones de antagonista de il-6 y sus usos.
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
WO2016004213A3 (en) Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them
EA201991951A1 (ru) Низковязкие высококонцентрированные составы на основе эволокумаба и способы их получения
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
EP4406969A3 (en) Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
MX2019015071A (es) Composiciones y metodos para tratar tauopatias.
MX2020005373A (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis.
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
PH12018502139A1 (en) Phosphaplatin liquid formulations
MX2020007559A (es) Formulaciones farmaceuticas.
ZA202002480B (en) Methods for treating or preventing asthma by administering an il-4r antagonist
HK1240487A1 (en) Methods for formulating antibody drug conjugate compositions
AR112928A1 (es) Composiciones y métodos para la administración de aav